The German Reimbursement Amount Is Decided in the Study Design

Reimbursement negotiations have a reputation as price talks. That misses the point. By the time the GKV-Spitzenverband and a company sit down together, the range of possible outcomes has already been fixed by a different procedure: the G-BA decision on added benefit and on the appropriate comparator therapy. Anyone who wants to influence the price therefore has to start years earlier, at the point where a study's comparator and endpoints are chosen.

The timetable leaves no room to catch up

The chain is tightly scheduled:

• The dossier is due at market launch.
• The benefit assessment is published three months later, usually prepared by IQWiG on behalf of the G-BA.
• The G-BA decision on the extent of added benefit follows no later than six months after launch.
• A six-month negotiation phase under Section 130b SGB V then begins. If no agreement is reached, an arbitration board decides.
• The reimbursement amount applies from the seventh month after first market launch.

Between authorisation and an effective reimbursement amount there is therefore a good half year in which the freely set launch price applies. For the argument inside the procedure, though, that window is already history: the dossier was due on day one.

The guardrails tie the amount to the comparator therapy

With the GKV-Finanzstabilisierungsgesetz, the legislator introduced limits in Section 130b(3) SGB V that couple negotiating headroom to the decision:

• No added benefit and the appropriate comparator therapy is a medicine whose patent and data protection have expired: the reimbursement amount should not lead to higher annual therapy costs than the comparator therapy.
• Minor or non-quantifiable added benefit and the comparator therapy is still under patent or data protection: the reimbursement amount must not lead to higher annual therapy costs than the comparator therapy.
• Where several alternatives have been determined as appropriate comparator therapy, the most economical one by annual therapy costs applies.

The arithmetic is therefore in plain sight: pricing headroom follows from the extent of added benefit and from the cost of the comparator therapy. Both are outputs of the assessment procedure, and both depend on the question of whom the product was compared against and on which endpoints. In its decision of 7 May 2025, the Federal Constitutional Court left two constitutional complaints against price regulation measures of the GKV-FinStG without success. The guardrails should not be treated as a transitional phenomenon.

Three further mechanisms that shift the return

• Combination discount, Section 130e SGB V. Medicines with new active ingredients used in a combination named by the G-BA are subject to a 20 percent discount on the manufacturer's selling price excluding VAT. The naming happens through the Pharmaceuticals Directive. The discount lapses with future effect if the G-BA determines at least considerable added benefit for the combination. For portfolios built around combinations this is a business-case parameter, not a footnote.
• Revenue threshold for orphan medicines. Under Section 35a(1) sentence 11 SGB V, added benefit is deemed proven upon authorisation. If revenue at the expense of statutory health insurance exceeds 30 million euros within twelve months, that presumption falls away and a regular assessment follows. Before the GKV-FinStG the threshold was 50 million euros. In other words, the product's success triggers the procedure that can constrain its price.
• Confidential reimbursement amount, Section 130b(1c) SGB V. For active ingredients first negotiated after 1 January 2025, the reimbursement amount can be exempted from reporting to public price and product directories. The condition is evidence to the GKV-Spitzenverband that the company operates its own pharmaceutical research unit within the scope of SGB V, pursues relevant projects of its own and maintains cooperations with public institutions. The evidence is deadline-bound: within five days of concluding the negotiation, or within six months of first market launch.

Why the German price matters beyond Germany

Germany is one of the most frequently used reference markets in Europe; according to analyses by the WHO Collaborating Centre it is part of the reference basket in roughly half of the countries examined. A German amount negotiated low or published early therefore travels into other markets through external price referencing. This is precisely where the confidentiality option earns its value, and precisely why the decision on the launch price is never a purely German one.

For MedTech the same logic sits in a different provision

For methods using high-risk medical devices, Section 137h SGB V applies: when a hospital submits a first request under Section 6(2) KHEntgG for a new reimbursement item, it transmits to the G-BA, in agreement with the manufacturer, the state of scientific knowledge including complete study data. An assessment takes place where the method rests on a new theoretical and scientific concept. Here too, the evidence available at the time of the request decides the revenue path. Supplying it later is not a procedural step.

What to do now

• Work the guardrails backwards. For every plausible decision scenario, model the annual therapy costs of the possible comparator therapies. That yields the price corridor before it is negotiated.
• Treat the comparator as a pricing decision. Choosing the comparator in the study design is the single most effective pricing decision in the whole life cycle, and it is taken years before the first negotiation round.
• Put combinations and the revenue threshold into the business case. A 20 percent discount and an assessment triggered by commercial success are foreseeable, not surprises.
• Check the confidentiality option early. Evidence on research and cooperations in Germany cannot be assembled in five days.

Entourage helps pharma, biotech, MedTech and IVD companies do this arithmetic before launch: deriving price corridors from the guardrails, modelling comparator therapy costs, assessing the combination discount and the revenue threshold for the portfolio at hand, and preparing negotiation materials together with the added-benefit argument.